Cardioprotective Effects of Pioglitazone in Type 2 Diabetes.
Tripathy, Devjit Solis-Herrera, Carolina
Tripathy, Devjit
Solis-Herrera, Carolina
Abstract
Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.
MIDER Authors
Citations
Altmetric:
Date
2021-08-18
Type
Article
Subject
Diabetes, Endocrinology
Collections
Citation
Tripathy D, Solis-Herrera C, Ryder REJ. Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. Diabetes Spectr. 2021 Aug;34(3):243-247.
Journal / Source Title
DOI
10.2337/ds20-0078
PMID
34511850
Publisher
American Diabetes Association